MedTrace Logo

SSSI Efficacy With iACB and PC-LIA in TKA Pain Management

NCT07191964 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-04-01

No results posted yet for this study

Summary

This prospective, triple-blinded, sham-controlled randomized trial evaluates the additive effect of Supra-Sartorial Subcutaneous Infiltration (SSSI) combined with intermittent adductor canal block (iACB) and posterior capsule local infiltration analgesia (PC-LIA) for pain management in total knee arthroplasty (TKA). SSSI, a simpler alternative to targeted anterior femoral cutaneous nerve (AFCN) block, is tested in 90 adults (45-90 years) randomized into two arms: sham SSSI + active iACB + PC-LIA versus all active interventions. Primary outcome is pain scores on postoperative day 0; secondary outcomes include daily pain trajectory, opioid use, functional recovery, and complications over days 0-3.

Conditions

  • Postoperative Pain Management in Total Knee Arthroplasty
  • Peripheral Nerve Blocks

Interventions

PROCEDURE

Supra-Sartorial Subcutaneous Infiltration (SSSI)

20 mL ropivacaine or saline infiltrated lateral-to-medial subcutaneously above sartorius at femoral triangle apex using inject-as-you-advance technique, avoiding hyperechoic nerves.

PROCEDURE

intermittent adductor canal block (iACB)

An adductor canal catheter is inserted proximal-to-distally over a distance of 6-10 cm at femoral triangle apex, with an initial bolus of 10 mL of 0.3% ropivacaine administered in PACU. The following doses start at 9:00 PM on the day of surgery and are repeated every 12 hours,

PROCEDURE

posterior capsule local infiltration analgesia (PC-LIA)

PC-LIA consists of two 10 mL injections of 0.3% ropivacaine delivered intraoperatively to the posteromedial and posterolateral aspects of the posterior capsule before cementation. The target injection plane is the potential space between the posterior capsule and the popliteal artery.

Sponsors & Collaborators

  • Taipei Medical University WanFang Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2027-06-30
Completion
2027-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07191964 on ClinicalTrials.gov